Suppr超能文献

通过 ascochlorin 对 ERK 磷酸化的调节,抑制 c-Myc 增强了 p21 介导的 G1 细胞周期阻滞。

Suppression of c-Myc enhances p21 -mediated G1 cell cycle arrest through the modulation of ERK phosphorylation by ascochlorin.

机构信息

Research Institute of Biomedical Engineering and Department of Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.

Department of Neural Development and Disease, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea.

出版信息

J Cell Biochem. 2018 Feb;119(2):2036-2047. doi: 10.1002/jcb.26366. Epub 2017 Oct 4.

Abstract

Numerous anti-cancer agents inhibit cell cycle progression via a p53-dependent mechanism; however, other genes such as the proto-oncogene c-Myc are promising targets for anticancer therapy. In the present study, we provide evidence that ascochlorin, an isoprenoid antibiotic, is a non-toxic anti-cancer agent that induces G1 cell cycle arrest and p21 expression by downregulating of c-Myc protein expression. Ascochlorin promoted the G1 arrest, upregulated p53 and p21 , and downregulated c-Myc in HCT116 cells. In p53-deficient cells, ascochlorin enhanced the expression of G1 arrest-related genes except p53. Small interfering RNA (siRNA) mediated c-Myc silencing indicated that the transcriptional repression of c-Myc was related to ascochlorin-mediated modulation of p21 expression. Ascochlorin suppressed the stabilization of the c-Myc protein by inhibiting ERK and P70S6K/4EBP1 phosphorylation, whereas it had no effect on c-Myc degradation mediated by PI3K/Akt/GSK3β. The ERK inhibitor PD98059 and siRNA-mediated ERK silencing induced G1 arrest and p21 expression by downregulating c-Myc in p53-deficient cells. These results indicated that ascochlorin-induced G1 arrest is associated with the repression of ERK phosphorylation and c-Myc expression. Thus, we reveal a role for ascochlorin in inhibiting tumor growth via G1 arrest, and identify a novel regulatory mechanism for ERK/c-Myc.

摘要

许多抗癌药物通过依赖 p53 的机制抑制细胞周期进展;然而,其他基因如原癌基因 c-Myc 是癌症治疗的有前途的靶点。在本研究中,我们提供的证据表明,穿心莲内酯,一种异戊烯抗生素,是一种非毒性的抗癌药物,通过下调 c-Myc 蛋白表达诱导 G1 细胞周期停滞和 p21 表达。穿心莲内酯促进 HCT116 细胞的 G1 期阻滞,上调 p53 和 p21 ,下调 c-Myc。在 p53 缺陷细胞中,穿心莲内酯增强了除 p53 之外的 G1 期阻滞相关基因的表达。小干扰 RNA(siRNA)介导的 c-Myc 沉默表明,c-Myc 的转录抑制与穿心莲内酯介导的 p21 表达调节有关。穿心莲内酯通过抑制 ERK 和 P70S6K/4EBP1 磷酸化来抑制 c-Myc 蛋白的稳定,而对 PI3K/Akt/GSK3β 介导的 c-Myc 降解没有影响。ERK 抑制剂 PD98059 和 siRNA 介导的 ERK 沉默通过下调 p53 缺陷细胞中的 c-Myc 诱导 G1 期阻滞和 p21 表达。这些结果表明,穿心莲内酯诱导的 G1 期阻滞与 ERK 磷酸化和 c-Myc 表达的抑制有关。因此,我们揭示了穿心莲内酯通过 G1 期阻滞抑制肿瘤生长的作用,并确定了 ERK/c-Myc 的新调节机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验